In vitro evaluation of new surface coatings for extracorporeal circulation

Perfusion

Volumn 14, Issue 1, 1999, Pages 11-19

  Baksaas, Svein T ^a   Videm, Vibeke ^b   Fosse, Erik ^a   Karlsen, Harald ^a   Pedersen, Thore ^a   Mollnes, Tom E ^c,d   Hagve, Tor A ^a   Svennevig, Jan L ^a  

^a UNIVERSITY OF OSLO   (Norway)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^c NORDLAND HOSPITAL   (Norway)

^d UNIVERSITY OF TROMSØ   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

BETA THROMBOGLOBULIN; COMPLEMENT COMPONENT C3; HEPARIN; MYELOPEROXIDASE; POLYMER;

ARTICLE; CARDIOPULMONARY BYPASS; CELL ACTIVATION; COMPARATIVE STUDY; COMPLEMENT ACTIVATION; COMPLEMENT BLOOD LEVEL; CONTROLLED STUDY; ENZYME BLOOD LEVEL; ENZYME IMMUNOASSAY; EVALUATION; EXPERIMENTAL MODEL; EXTRACORPOREAL CIRCULATION; GRANULOCYTE; HEMATOLOGICAL PARAMETERS; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IN VITRO STUDY; INFLAMMATION; INTEGRATED CIRCUIT; LEUKOCYTE ACTIVATION; NORMAL HUMAN; OXYGENATOR; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STATISTICAL ANALYSIS; SURFACE PROPERTY; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT;

EID: 0032939274     PISSN: 02676591     EISSN: None     Source Type: Journal    
DOI: 10.1177/026765919901400103     Document Type: Article

References (28)

1. Kirklin JK. The post-perfusion syndrome: inflammation and the damaging effect of cardiopulmonary bypass. In: Tinker J ed. Cardiopulmonary bypass: current concepts and controversies. Philadelphia, PA: WB Saunders, 1989: 131-46.
2. Faymonville ME, Pincemail J, Duchateau J et al. Myeloperoxidase and elastase as markers of leukocyte activation during cardiopulmonary bypass in humans. J Thorac Cardiovasc Surg 1992; 102: 309-17.
3. Moore FD Jr, Warner KG, Assousa S, Valeri CR, Khuri SF. The effects of complement activation during cardiopulmonary bypass. Attenuation by hypothermia, heparin and hemodilution. Ann Surg 1988; 208: 95-103.
4. Baksaas ST, Videm V, Mollnes TE, Pedersen T, Karisen H, Svennevig JL. Effects on complement, granulocytes and platelets of a leukocyte-depletion filter during in vitro extracorporeal circulation. Scand Cardiovasc J 1997; 31: 73-78.
5. Edmunds LH Jr. Surface-bound heparin - panacea or peril? Ann Thorac Surg 1994; 58: 285-86.
6. Gott VL, Whiffen JD, Dutten RC. Heparin bonding on colloidal graphite surfaces. Science 1963; 142: 1297-98.
7. Larm O, Larsson R, Olsson P. A new nonthrombogenic surface prepared by selective binding of heparin via a modified reducing terminal residue. Biomat Med Dev Artif Org 1983; 11: 161-73.
8. Svennevig JL, Geiran OR, Karlsen H et al. Complement activation during extracorporeal circulation. J Thorac Cardiovasc Surg 1993; 106: 466-72.
9. Andrade JD. Surfaces and blood compatibility: current hypothesis. Trans ASAIO 1987; 33: 75-84.
10. Lee JH, Kopecek J, Andrade J. Protein-resistent surfaces prepared by PEO-containing block copolymer surfactants. J Biomat Mat Res 1989; 23: 351-68.
11. Han DK, Jeong SY, Kim YH. Evaluation of blood compatibility of PEO grafted and heparin immobilized polyurethanes. J Biomed Mat Res: Appl Biomaterials 1989; 23: 211-28.
12. Sederal LC. Anticoagulant activity of a synthetic heparinoid in relation to molecular weight and N-sulphate content. J Biomed Mat Res 1981; 15: 819-27.
13. Ito Y, Iguchi Y, Kashiwagi T, Imanishi Y. Synthesis and nonthrombogenicity of polyetherurethaneurea film grafted with polysodium vinyl sulphonate. J Biomed Mat Res 1991; 25: 1347-61.
14. Silver JH, Hart AP, Williams EC et al. Anticoagulant effects of sulphonated polyurethanes. Biomaterials 1992; 13: 339-44.
15. Sawyer PN. Electrical potential differences across the normal aorta and aortic grafts in dogs. Am J Physiol 1953; 175: 113-17.
16. Videm V, Nilsson L, Venge P, Svennevig JL. Reduced granulocyte activation with a heparin coated device in an in vitro model of cardiopulmonary bypass. Artif Organs 1991; 15: 90-95.
17. Garred P, Mollnes TE, Lea T. Quantification in enzyme-linked immunosorbent assay of a C3 neoepitope expressed on activated human complement factor C3. Scand J Immunol 1988; 27: 329-35.
18. Mollnes TE, Lea T, Frøland SS, Harboe M. Quantification of the terminal complement complex in human plasma by an enzyme-linked immunosorbent assay based on monoclonal antibodies against a neoantigen of the complex. Scand J Immunol 1985; 22: 197-202.
19. Videm V. Heparin in clinical doses 'primes' granulocytes to subsequent activation as measured by myeloperoxidase release. Scand J Immunol 1996; 43: 385-90.
20. Noether G. Introduction to statistics: A nonparametric approach, 2nd edn. Boston, MA: Houghton Mifflin, 1976: 128-35.
21. Nilsson L, Brunnkvist S, Nilsson U et al. Activation of inflammatory systems during cardiopulmonary bypass. Scand J Thorac Cardiovasc Surg 1988; 22: 51-53.
22. Fosse E, Moen O, Johnson E et al. Reduced complement and granulocyte activation with heparin-coated cardiopulmonary bypass. Ann Thorac Surg 1994; 58: 472-77.
23. Moen O, Fosse E, Brockmeier V et al. Disparity in blood activation by two different heparin coated cardiopulmonary bypass systems. Ann Thorac Surg 1995; 60: 1317-23.
24. Borowiec J, Thelin S, Bagge L, Nilsson L, Venge P, Hansson HE. Heparin-coated circuits reduce activation of granulocytes during cardiopulmonary bypass. J Thorac Cardiovasc. Surg 1992; 104: 642-47.
25. Øvrum E, Brosstad F, Holen EÅ, Tangen G, Abdelnoor M. Effects on coagulation and fibrinolysis with reduced versus full systemic heparinization and heparin-coated cardiopulmonary bypass. Circulation 1995; 92: 2579-84.
26. Gu YJ, van Oeveren W, van der Kamp KWJH et al. Heparin coating extracorporeal circuits reduces thrombin formation in patients undergoing cardiopulmonary bypass. Perfusion 1991; 6: 221-25.
27. Mollnes TE, Riesenfeld J, Garred P et al. A new model for evaluation of biocompatibility: combined determinations of neoepitopes in blood and on artificial surfaces demonstrates reduced complement activation by immobilization of heparin. Artif Organs 1995; 19: 909-17.
28. Videm V, Fosse E, Mollnes TE, Ellingsen Ø, Pedersen T, Karlsen H. Different oxygenators for cardiopulmonary bypass lead to varying degrees of human complement activation in vitro. J Thorac Surg 1989; 97: 764-70.